Roche, Mylan settle Xeloda patent fight; Paladin to lodge Valeant-beating bid for Afexa;

@FiercePharma: CHMP on Multaq: Use after considering alternatives, and only in certain AF patients. For them, benefits > risks $SNY. Item | Follow @FiercePharma

> Roche and Mylan ($MYL) have settled a patent fight over the cancer drug Xeloda with a deal subject to review by the Justice Department and Federal Trade Commission. Details weren't disclosed, but Xeloda's patent is due to expire in 2013. News

> MSMB Capital Management moved to oust all but one of Amag Pharmaceuticals' ($AMAG) directors and block its proposed merger with Allos Therapeutics ($ALTH). Report

> Paladin Labs ($PLB) plans to sweeten its bid for Canada's Afexa Life Sciences ($FXA) enough to top an offer from Valeant Pharmaceuticals ($VRX). Article

> Roche's ($ROG) Avastin won approval from Europe's CHMP for use as a first-line treatment against advanced ovarian cancer in combination with chemo. Roche release

> Gilead Sciences' ($GILD) combination HIV drug Eviplera got a positive recommendation from CHMP, and a decision is expected from the European Commission by year's end. Gilead release

> Novartis' ($NVS) proposed triple-combination blood pressure pill Rasitrio--which comprises the renin inhibitor Rasilez, plus a calcium channel blocker and diuretic--won a positive opinion from Europe's CHMP. Novartis release

Biotech News

 @FierceBiotech: The Latest Sirtuin Controversy. Article Read the excellent article by @Dereklowe. | Follow @FierceBiotech

 @JohnCFierce: In case you missed it: Enzon is chopping its workforce in half. Article | Follow @JohnCFierce

 @RyanMFierce: Anyone really surprised $AZ is going with partner over M&A strategy in China, though? Not aware of many biotechs there ripe for takeovers. | Follow @RyanMFierce

 @MaureenFierce: RT @Loftus: Merck rotavirus vaccine cut hospitalizations, spending, according to CDC. Report | Follow @MaureenFierce

 @FierceMedDev: More exec moves at AngioDynamics: Scott Solano to Depart AngioDynamics. Release | Follow @FierceMedDev

> FDA slams brakes on Immunomedics' cancer trial. Story 

> Getting the most out of your first-in-human studies. News 

> Icahn-backed Enzon Pharma axing half of workers. Item 

And Finally... Anti-wrinkle supplement from Unilever tested in double-blind trial, but how good is the data? Report

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.